Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.